A revolution in the efficacy of inhaled drugs
Aquilon Pharma aims to play a disruptive role in the next generation formulation technology for inhaled medication by improving the efficacy of inhaled drug.
About us
With its scientific roots in Liège University, Aquilon Pharma is an independent PharmaTech company, specialized in the improvement of the efficacy of drugs, administered through inhalation.
Aquilon in numbers
dedicated team members
innovative products
€-Million Aquilon valuation
achieved clinical trials
ongoing clinical trials
Our technology
HP-Betadex is one of the selected functional excipients for inhalation. This excipient technology improves both the pharmacology and the lung deposition of existing drugs.
Our portfolio
Aquilon Pharma focuses on asthma, COPD and Nasal. Our formulations are compatible with all devices.
Our latest news
Aquilon Pharma has signed a purchase order for ISAB’s high-precision R&D system PreciseInhale®
Aquilon Pharma launches a Phase II clinical trial for Covid19 patients in the acute respiratory phase
New laboratories
Collective representative office in Texas
News Release
Board reshuffle at Aquilon Pharmaceuticals
Aquilon and partners cross the mid-term milestone for Aeronext
Aquilon proves the high potential of HP-Betadex in Dry Powder formulation
A highly experienced team
The Aquilon Pharma drug development team is working on the technical aspects, such as pharmacology, toxicology, clinical studies, pharmaceutical development, etc.
Our partners
Would you like to be a partner of Aquilon Pharma?
Follow us
Stay up to date by following our media channels for our very latest news
Contact us
Do you have a question? Let's get in touch.